CASSAVA SCIENCES INC.

Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints

25 ноя 2024 07:30:00 Источник Nasdaq GlobeNewswire

Cassava Sciences to Hold Corporate Update on November 25th

24 ноя 2024 20:01:09 Источник Nasdaq GlobeNewswire

Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer

18 ноя 2024 08:30:00 Источник Nasdaq GlobeNewswire

Cassava Sciences Reports Q3 2024 Financial and Operating Results

07 ноя 2024 07:55:00 Источник Nasdaq GlobeNewswire

Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024

31 окт 2024 08:30:00 Источник Nasdaq GlobeNewswire

Cassava Sciences Resolves SEC Investigation

26 сен 2024 18:15:00 Источник Nasdaq GlobeNewswire

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

24 сен 2024 08:30:00 Источник Nasdaq GlobeNewswire

Cassava Sciences Names Rick Barry as Chief Executive Officer

09 сен 2024 08:30:00 Источник Nasdaq GlobeNewswire

Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference

03 сен 2024 08:31:00 Источник Nasdaq GlobeNewswire

Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates

08 авг 2024 08:00:01 Источник Nasdaq GlobeNewswire

Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson

05 авг 2024 09:01:00 Источник Nasdaq GlobeNewswire

Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET

01 авг 2024 08:30:00 Источник Nasdaq GlobeNewswire

Cassava Sciences Announces Expansion of Open-Label Extension Trials

30 июл 2024 08:15:00 Источник Nasdaq GlobeNewswire

Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives

17 июл 2024 08:00:00 Источник Nasdaq GlobeNewswire

Cassava Sciences Issues Statement on Former Science Advisor

28 июн 2024 15:58:09 Источник Nasdaq GlobeNewswire

Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam

10 май 2024 16:02:00 Источник Nasdaq GlobeNewswire

Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution

08 май 2024 11:00:00 Источник Nasdaq GlobeNewswire

Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ

01 май 2024 09:10:00 Источник Nasdaq GlobeNewswire

Redemption Date Announced for Warrants

15 апр 2024 09:20:00 Источник Nasdaq GlobeNewswire

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

25 мар 2024 09:13:00 Источник Nasdaq GlobeNewswire